RNA Virus Infections Clinical Trial
— GeBVirOfficial title:
DNA and RNA Viruses of the Blood Virome of Allogeneic Hematopoietic Stem Cell Transplant Recipients: a Longitudinal Observational Study During a One-year Period After Transplantation - the Geneva Blood Virome Project (GeBVir)
Verified date | January 2021 |
Source | University Hospital, Geneva |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The Geneva Blood Virome Project is a longitudinal observational study. The main objective is to describe the kinetics of the plasmatic viral load of a selection of at least 21 DNA and RNA viruses of the blood virome in allogeneic hematopoietic stem cell transplant recipients, over a one-year period after transplantation. Secondary objectives are: 1) to assess the prevalence of DNA and RNA viruses plasmatic detections and co-detections, 2) to assess the cumulative incidence of DNA and RNA viruses plasmatic detection. The population of the study consists in adult patients receiving allogeneic stem cell transplantation at the University Hospitals of Geneva, enrolled in an already existing monocentric cohort, and for which clinical specimens are collected and stored at the time and after transplantation. The investigators plan to include 120 patients whose plasma samples are collected from March 2017 and to systematically use plasma samples collected on the day of transplantation and several time points after transplantation to screen DNA and RNA viruses by qualitative and quantitative real-time PCR and RT-PCR.
Status | Completed |
Enrollment | 112 |
Est. completion date | December 31, 2020 |
Est. primary completion date | December 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult patients receiving allogeneic stem cell transplantation since March 2017 at University Hospitals of Geneva - Enrollment in the "Cohort of infectious disease in hematopoietic stem cell transplant patients" - Signature of an informed consent form before transplantation Exclusion Criteria: - Absence of a signed informed consent form for the "Cohort of infectious disease in hematopoietic stem cell transplant patients". |
Country | Name | City | State |
---|---|---|---|
Switzerland | University Hospitals of Geneva | Geneva |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Geneva | Dr Diem-Lan Vu Cantero, Dr Dionysios Neofytos, Dr Federico Simonetta, Dr Samuel Cordey, Dr Stavroula Masouridi-Levrat, Prof Christian Van Delden, Prof Laurent Kaiser, Prof Yves Chalandon |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Plasmatic viral load kinetics of DNA and RNA viruses | Measurement of the plasmatic viral load of DNA and RNA viruses belonging to the Herpesviridae, Polyomaviridae, Adenoviridae, Parvoviridae, Anelloviridae, Picornaviridae and Flaviviridae families, with real time (RT-)PCR on plasma samples collected at pre-specified timepoints (the day of transplantation (D0), 30 days (D30), 3 months (M3), 6 months (M6) and one year (Y1) after transplantation) (expressed as fold-increase). | one-year period after transplantation | |
Secondary | Prevalence of plasmatic detection of DNA and RNA viruses | Detection of DNA and RNA viruses using real time (RT-)PCR performed on plasma samples collected at pre-specified timepoints | one-year period after transplantation | |
Secondary | Cumulative incidence of DNA and RNA viruses plasmatic detection | Detection of DNA and RNA viruses using real time (RT-)PCR performed on plasma samples collected at pre-specified timepoints | one-year period after transplantation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT04644484 -
A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety
|
Phase 3 | |
Completed |
NCT00984945 -
Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults
|
Phase 1 | |
Active, not recruiting |
NCT05284097 -
Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study
|
Phase 2 | |
Completed |
NCT03739112 -
Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
|
Phase 3 | |
Completed |
NCT01991587 -
Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults
|
Phase 1/Phase 2 | |
Completed |
NCT03294473 -
Centralized Reminder Recall - Flu RCT2
|
N/A | |
Completed |
NCT01244867 -
Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza Vaccine
|
Phase 2 | |
Not yet recruiting |
NCT05394623 -
Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)
|
||
Recruiting |
NCT03776760 -
Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination
|
||
Completed |
NCT04517682 -
COVID-19 and SARS-CoV-2 Detection in Saliva
|
||
Active, not recruiting |
NCT04365101 -
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05307991 -
Integrating Enhanced HIV PrEP Into a STI Clinic in Lilongwe
|
||
Completed |
NCT03110770 -
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
|
Phase 2 | |
Completed |
NCT04772469 -
Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men
|
N/A | |
Terminated |
NCT02120274 -
Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C
|
Phase 4 | |
Completed |
NCT02768805 -
Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults
|
Phase 2 | |
Recruiting |
NCT04627623 -
Prevalence and Risk Factors of COVID-19 in the Upper Silesian Agglomeration
|
||
Completed |
NCT01991561 -
Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.
|
Phase 2 | |
Completed |
NCT01587131 -
DNA-based Influenza Vaccine in the Elderly
|
Phase 1 |